论文部分内容阅读
本研究观察了肿瘤坏死因子、胸腺肽与化疗药物联合治疗中晚期原发性肝癌的疗效.89例中晚期肝癌患者随机分为免疫化疗组(治疗组)42例和化疗组(对照组)47例,治疗组同时配合肿瘤坏死因子和胸腺肽免疫治疗,结果显示,治疗组中位肿瘤缩小率明显高于对照组(P<0.01);AFP下降明显(P<0.05),对照组下降不明显(P>0.05);治疗组较对照组1/2、1、2年生存率分别提高28.6%.18.0%、5.1%(P<0.05),这表明,该法治疗中晚期肝癌能提高患者的免疫功能,提高其生存质量,延长生存期,具有一定的应用前景.
This study investigated the efficacy of TNF, thymosin and chemotherapeutic drugs in the treatment of advanced primary liver cancer. 89 patients with advanced liver cancer were randomly divided into immunochemotherapy group (treatment group) 42 cases and chemotherapy group (control group) 47 cases. The treatment group also received immunotherapy with tumor necrosis factor and thymosin. The results showed that the median tumor shrinkage rate in the treatment group was significantly higher than that in the control group (P<0.01); AFP decreased significantly (P<0.05), but the control group did not decrease significantly (P<0.05). >0.05); The 1/2, 1 and 2 year survival rates of the treatment group were increased by 28.6%, 18.0%, and 5.1%, respectively, compared with the control group (P<0.05). This indicates that the treatment of advanced liver cancer can improve the patient’s immune function. , to improve its quality of life, to extend the survival period, has a certain application prospects.